Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/News/Novo Nordisk Takes a Stand: Sues Hims & Hers Over Controversial Compounded Obesity Drugs!
News

Novo Nordisk Takes a Stand: Sues Hims & Hers Over Controversial Compounded Obesity Drugs!

By adminitfy
February 9, 2026 3 Min Read

Novo Nordisk, the pharmaceutical giant behind the popular obesity treatment Wegovy, has initiated legal action against the online telehealth provider Hims & Hers for allegedly distributing unapproved and cheaper versions of its medication in the U.S. The lawsuit seeks to permanently ban Hims from selling compounded versions of Wegovy, asserting that these products infringe on Novo’s patents and may jeopardize patient safety due to lack of regulatory oversight.

In a statement, Novo accused Hims of “deceiving patients and putting their health at risk” by marketing these unapproved alternatives, emphasizing that their safety, efficacy, and quality remain unverified by U.S. regulatory bodies. This legal battle intensifies the ongoing rivalry between the two companies, particularly after Hims announced its decision to halt the sale of its obesity pill in response to scrutiny from federal regulators and threats of litigation from Novo.

While Hims had initially offered its version of Wegovy for as low as $49 in the first month-about $100 less than the approved medication-Novo Nordisk has seen a 7.1% rise in its Copenhagen-listed shares, reflecting investor confidence amid this competitive landscape. Conversely, shares of Hims plummeted by 19% during early trading as concerns mounted over the legitimacy of its product offerings.

This legal dilemma unfolds against the backdrop of a burgeoning obesity drug market, where Novo is striving to regain its footing amid competition from Eli Lilly and other compounded alternatives. Compounding pharmacies have exploited regulatory loopholes to market versions of patent-protected medications when the branded products are reportedly in short supply. However, Novo’s efforts to boost manufacturing have eliminated shortages of semaglutide, the active ingredient in Wegovy and its other major injections.

Despite semaglutide being under patent protection until 2032, Hims asserts that its compounded versions are legally permissible because they are “personalized” in dosage. However, Novo has firmly stated that it does not supply semaglutide to compounding pharmacies and accused Hims of engaging in illegal practices by mass-compounding unapproved versions of Wegovy and Ozempic.

John Kuckelman, Novo’s senior vice president and general counsel, remarked, “Hims is mass marketing unapproved knock-off versions of Wegovy and Ozempic that evade the FDA’s gold standard review process. This is dangerous and deceptive to patients and undermines the scientific innovation and regulatory rigor established to ensure these treatments are safe and effective.”

In a related development, the Food and Drug Administration (FDA) has announced plans to take legal action against Hims, which could include restricting access to the ingredients used in these compounded drugs and referring the case to the Department of Justice for potential violations.

Both Novo Nordisk and Eli Lilly have intensified their efforts to combat compounding pharmacies, which have significantly benefited from the rising demand for weight-loss and diabetes medications. Lilly previously navigated similar legal challenges regarding its weight-loss medication and diabetes treatment that also saw a surge in demand.

As this story continues to evolve, the implications for patient safety and the legal landscape surrounding compounded medicines remain significant, highlighting a contentious intersection of innovation and regulation in the pharmaceutical industry.

Tags: Novo Nordisk, Hims & Hers, Wegovy, semaglutide, FDA, obesity treatment, patent infringement, telehealth, compounded drugs, legal action.

Original Source: https://www.cnbc.com/2026/02/09/novo-nordisk-sues-hims-hers-compounded-obesity-drugs.html
Category :
Tags:
Publish Date: 2026-02-09 17:57:00

Author

adminitfy

Follow Me
Other Articles
Alarming Rise in Sonitpur Elephant Deaths Despite Conflict Management
Previous

Alarming Rise in Sonitpur Elephant Deaths Despite Conflict Management

Meghalaya: The Only Northeast State Supporting Private Schools with Grants
Next

Meghalaya’s Bold Education Reset: Too Many Schools, Few Students

No Comment! Be the first one.

Leave a Reply Cancel reply

You must be logged in to post a comment.

Search...

Recent Posts

  • 511 Bags of Urea Seized in Assam's Cachar; Two Arrested
    511 Bags of Urea Seized in Assam’s Cachar; Two Arrested
    by adminitfy
    November 21, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • 511 Bags of Urea Seized in Assam’s Cachar; Two Arrested
  • Manipur Spurious Liquor Tragedy: 11 Dead, 300+ Hospitalized
  • UPI’s Pricing Reckoning: Designing a Sustainable Payments Network
  • ABKU Urges Amit Shah to Halt 11,200-MW Siang Dam Over Displacement
  • Nepal PM Balendra Shah to Meet India’s Modi on First Foreign Trip
  • November 2026 (651)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.